CONICET | Buscador de Institutos y Recursos Humanos

Lacticaseibacillus rhamnosus CRL1505 and its cell wall are able to enhance basal myelopoiesis in cyclophosphamide (Cy)-affected bone marrow. The aim of this work was to study the immunomodulatory effect of the inmunobiotic L. rhamnosus CRL1505 and its postbiotic (cell wall) on basal myelopoiesis deteriorated by chemotherapy treatment during a tumor process. In vitro, 4T1 breast cancer cells were treated with Cy in the presence or absence of CRL1505 postbiotic. Cell viability was evaluated by flow cytometry. In vivo, BALB/c mice bearing breast cancer treated with Cy or not, were administered the CRL1505 strain or its cell wall during 20 days. Tumor growth, bone marrow and blood cell counts, lung histology and serum cytokines were evaluated. First, we demonstrated that CRL1505 cell wall does not interfere with Cy toxicity in 4T1 breast cancer cells. In addition, mice treated with Cy plus L. rhamnosus CRL1505 showed a significant reduction in tumor size compared to the Cy control. While the CRL1505 strain and its cell wall were effective treatments to reduce leukocyte, neutrophil and Px+ cell counts in peripheral blood, the immunobiotic strain was able to reduce the leukemoid reaction that accompanies the growth of this tumor. In the bone marrow, both oral supplements were able to increase the expression of CXCR4 and TLR2. However, only the immunobiotic strain was able to reduce granulocyte and macrophage progenitors. Finally, the CRL1505 strain and its postbiotic reduced splenomegaly, restored the myeloid/lymphoid ratio in the spleen, and the monocyte population in the liver. Therefore, the oral administration of L. rhamnosus CRL1505 or its cell wall exerts an adjuvant effect on chemotherapy treatment with cyclophosphamide in mice bearing breast cancer, observing the best benefits administering the viable bacteria, without producing adverse effects.

enviar mensaje